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CHF6001 is an inhaled phosphodiesterase 4 (PDE4) inhibitor in development for the treatment of
obstructive lung diseases. The efﬁcacy and safety of CHF6001 were investigated in a double blind, pla-
cebo controlled, 3-way cross-over study using the allergen challenge model.
Thirty-six atopic asthmatics who were not taking inhaled corticosteroids and who demonstrated a late
asthmatic response (LAR) to inhaled allergen at screening were randomised to receive CHF6001 400 mg or
1200 mg or placebo administered once a day using a dry powder inhaler. The three treatment periods
were 9 days; allergen challenges were performed on day 9 and induced sputum was obtained after 10 h
from challenge. Washout periods between treatments were up to 5 weeks.
Both CHF6001 doses signiﬁcantly attenuated the LAR; the primary endpoint analysis showed that
CHF6001 400 mg and 1200 mg caused reductions of 19.7% (p ¼ 0.015) and 28.2% (p < 0.001) respectively of
the weighted FEV1 AUC4e10h compared with placebo. The difference between the CHF6001 doses was not
statistically signiﬁcant (p ¼ 0.223). Compared with placebo, CHF6001 caused greater reduction in
sputum eosinophil counts, although these changes were not statistically signiﬁcant. CHF6001 was well
tolerated, with similar numbers of adverse events in each treatment period.
This inhaled PDE4 inhibitor has the potential to provide clinical beneﬁts in patients with atopic
asthma.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cyclic 3050-adenosine monophosphate (cAMP) and cyclic gua-
nosine monophosphate (cGMP) are intracellular signalling mole-
cules that regulate immune cell function [1]. Phosphodiesterase
(PDE) enzymes hydrolyse these second messengers thereby up-
regulating the activity of immune cells [2]. The PDE4 subtype is
selectively expressed in immune cells [2]; pharmacological tar-
geting of PDE4 increases cAMP and cGMP levels and thereby re-
duces immune cell activity. Orally administered PDE4 inhibitors
such as roﬂumilast have anti-inﬂammatory effects and clinicalLtd. This is an open access article ubeneﬁts in asthma and COPD, but also cause side effects such as
gastro-intestinal disturbance and weight loss due to systemic
exposure [3e6]. CHF6001 is a potent and selective PDE4 inhibitor
that is in development for the treatment of obstructive lung dis-
eases [7]. The compound is formulated as dry powder for delivery
by inhalationwith low aqueous solubility and oral bioavailability in
order to reduce the potential for systemic side effects. Intratracheal
delivery of CHF6001 has anti-inﬂammatory effects in different
animal models, including allergic inﬂammation in rats [7].
While there are more clinical data showing the clinical effects of
PDE4 inhibitors in COPD [3,4], there are a number of studies that
have shown that roﬂumilast improves lung function in patients
with asthma [6]. However, the side effect proﬁle of roﬂumilast has
prevented further development of this drug for asthma [5]. Inhalednder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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vide an extra option for the treatment of asthma.
The inhaled allergen challenge model is commonly used to
evaluate the anti-inﬂammatory effects of novel drugs at an early
stage in clinical development [8e11]. Patients with allergic asthma
can develop an early asthmatic response (EAR) due to mast cell
mediator-induced bronchoconstriction and a late asthmatic
response (LAR) due to airway inﬂammation in response to inhaled
allergen. The efﬁcacy and safety of CHF6001 were investigated in a




Thirty-six (36) patients with physician-diagnosed asthma who
had not been treated with inhaled corticosteroids for > 6 months
were recruited. Subjects were required to be aged 18e60 years and
non-smokers for at least 1 year with < 5 pack-year history. At
screening patients were required to have an FEV1 > 70% predicted,
have a positive skin test to either house dust mite, grass pollen or
cat allergen (ALK-Abello, Denmark), and to demonstrate both an
EAR and LAR to one of these allergens when inhaled. Exclusion
criteria are listed in the data supplement. All patients provided
written informed consent. The study was approved by the local
research ethics committee.
2.2. Study design
This was a three-centre, double-blind, randomised, placebo-
controlled, three way cross-over study. Patients who were sensitive
to grass pollen were enrolled outside the hay-fever season. Eligible
subjects were randomised to receive CHF6001 400 mg (one 400 mg
capsule plus two matching placebo capsules) or 1200 mg (three
400 mg capsules) or placebo (three placebo capsules) administered
once a day in the morning using a dry powder inhaler (Aerolizer™)
for 9 days. The washout period was 4e5 weeks between treatment
periods. A balanced block randomization scheme was used. The
treatment sequences were arranged according to a complete set of
3  3 Latin Square design (6 sequences). Patients were sequentially
assigned to the lowest available randomization number.
At screening, the following measurements were performed:
vital signs, ECG, forced expiratory volume in 1 s (FEV1), biochem-
istry and haematology blood tests, skin prick tests and inhaled
allergen challenge with induced sputum at 10 h post-allergen
challenge. At least 20 subjects able to produce adequate induced
sputum samples after allergen challenge at screening were
required, in order to increase the chance of a subgroup of patients
providing adequate sputum samples for analysis. Patients were
trained in inhaler technique at screening using the In-check Dial
device. The following measurements were performed at pre-dose
on day 1, 4 and 9 of each treatment period: FEV1, vital signs and
ECG. After dosing on day 9, an inhaled allergen challenge was
performed with collection of induced sputum 10 h after challenge.
Methacholine challenge was then performed 24 h post-allergen
challenge. Adverse events were collected throughout the study
using diary cards.
2.3. Allergen and methacholine challenges
Bronchial challenges were performed as previously described
[8,9], with full details in the on-line supplement. For allergen
challenge at screening, ascending concentrations from 250 SQ-U/
ml to 32,000 SQ-U/ml were administered using a MefarDosimeter (Mefar-Bologna) until an early asthmatic response (EAR)
was observed. The EAR was deﬁned as a fall in FEV1 of  20% from
the post-saline value, on at least one occasion, between 5 and
30 min after the ﬁnal concentration of allergen. The late asthmatic
response (LAR) at screening was deﬁned as a fall in FEV1 of  15%
from the post-saline value, on at least three occasions, two of which
must be consecutive, between 4 and 10 h after the ﬁnal allergen
concentration. After randomization, allergen challenges adminis-
tered a single dose of allergen which was the cumulative dose that
caused the LAR at screening. The EAR was measured from 0 to 2 h
post allergen, and the LAR from 4 to 10 h post-allergen.
2.4. Induced sputum
Induced sputum was obtained as previously described [9,12].
Sputum plugs were selected to separate sputum from saliva, and
then processed using dithiothreitol (DTT, Sigma Aldrich, Poole, UK).
Cell counts and viability were determined by the Trypan blue
exclusion method utilising a Neubauer haemocytometer. Cytospins
were prepared and stained with Rapi-diff (Triangle, Skelmersdale,
UK) for differential cell counts. Four hundred leukocytes were
counted and the results expressed as percentage of the total leu-
cocyte count and the total cell count (TCC). An adequate sputum
sample was deﬁned as >75 mg with a cell viability >40%. Sputum
supernatants were analysed for eosinophil cationic protein (ECP)
using MESACUP ECP kit (MBL international, Aichi, Japan; lower
limit of detection 0.125 ng/ml) and neutrophil elastase (NE) by
Luminex assay (Merck-Millipore, UK; lower limit of detection
20 pg/ml) on a Magpix analyser (Luminex, USA).
2.5. Pharmacokinetics
Blood samples were collected by venipuncture on day 9 in order
to obtain plasma for pharmacokinetic analysis. Plasma CHF6001
(the parent compound) and CHF5956 (ametabolite) concentrations
were determined at Quotient Bioresearch Ltd. (UK) using a vali-
dated LC-MS/MS method, with a lower quantiﬁcation limit (LQL) of
10 pg/mL for both analytes (validated range: 10e1,000 pg/mL). The
precision and accuracy were within ± 20% at the LQL and within ±
15% at all other concentrations.
2.6. Statistics
The primary efﬁcacy endpoint was the inhibition of the LAR on
Day 9, expressed as the area under curve (AUC) of the FEV1 percent
changes from post-diluent normalised by time (weighted AUC). The
post-diluent FEV1 measurement was used as the pre-challenge
reference value to calculate the change in FEV1 at each time point
assessment. These changes were expressed as follows:
1) absolute change: FEV1 at time t e FEV1 post-diluent.
2) percent change: (FEV1 at time t e FEV1 post-diluent)/FEV1 post-
diluent * 100.
The AUC of these changes was calculated using the linear trap-
ezoidal rule as follows:
AUC(t) ¼ cumulative AUC up to time t ¼ AUC(t1) þ 0.5 * (FEV1
% change from post-diluent (t1) þ FEV1 % change from post-
diluent (t)) * (time(t)-time(t1)).
The AUC normalised by time (or weighted AUC) was obtained by
dividing the AUC by time interval considered as follows: AUC/actual
time spanned by AUC.
A sample size of 24 evaluable patients ensures 85% power to
detect a difference of at least 30% in attenuating weighted LAR with
CHF6001 compared with placebo, with a 0.025 two-sided
Table 1
Demographic characteristics.




FEV1 (L) 3.4 ± 0.63
FEV1% Predicted 86.8 ± 11.17
Skin prick test sensitisationa
House dust mite 31
Cat 27
Grass pollen 28
Data are mean (SD) or n (%).
a Subjects may be sensitised to more than one allergen.
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compensate for approximately 20% non-evaluable rate, 30 patients
were to be randomised.
Secondary endpoints included: the inhibition of the LAR (from 4
to 10 h post-allergen challenge) on Day 9 measured as weighted
AUC of the FEV1 absolute changes and the maximum fall in FEV1
measured as the maximum decrease in the percent and absolute
change in FEV1; inhibition of the EAR (from 5 min to 2 h post
allergen challenge) on Day 9, deﬁned as the weighted AUC of the
FEV1 % and absolute changes and the maximum fall in FEV1
measured as the maximum decrease in the percent and absolute
change in FEV1; allergen-induced airway inﬂammatory cells and
mediators at 10 h post-allergen challenge; and responsiveness to a
methacholine (MCh) challenge post-allergen challenge (deﬁned as
the provocativeMCh concentration causing a 20% decrease in FEV1;
PC20 FEV1) and the pre-dose FEV1 on Day 4, Day 9 and Day 10.
The effects of treatment on the EAR and LAR were compared
using analysis of variance (ANOVA), including treatment, period
and patient as ﬁxed effects. The adjusted mean differences versus
placebo were calculated together with Dunnett’s simultaneous 95%
conﬁdence intervals and p-values. The same model was used to
analyse the MCh challenge PC20 FEV1 (after log2-transformation of
data) and the sputum parameters (after log-transformation of the
data). The results for CHF6001 and placebo were back transformed
and presented as adjusted geometric means, and the difference
between CHF6001 and placebo presented as a ratio of geometric
means (with 95% CI). FEV1 data were summarised by means of
descriptive statistics. Data analysis was generated using SAS soft-
ware (SAS Institute Inc., Cary, NC, USA).
3. Results
Thirty-six subjects were randomised (Table 1), with the
following allergens administered: house dust mite n¼ 22, cat n¼ 5,
grass pollen n ¼ 9. Thirty-three subjects completed the study. One
subject withdrew the consent and two others were withdrawn
because of adverse events during the ﬁrst treatment period. These
adverse events were an asthma exacerbation after 4 days of treat-
ment with CHF6001 400 mg, and a severe allergic reaction to
inhaled allergen after placebo treatment.
3.1. Allergen challenge
The time proﬁle of the FEV1 response to allergen challenge is
shown in Fig. 1. Both doses of CHF6001 signiﬁcantly attenuated the
LARcompared toplacebo. Theprimaryendpoint analysis showed that
CHF6001 400 mg and 1200 mg caused reductions of 19.7% (p ¼ 0.015)
and 28.2% (p < 0.001) respectively of the weighted FEV1 AUC4e10h (%
change) compared with placebo (Table 2). The effect on AUC4e10h (%
change) did not differ between the two CHF6001 doses (p ¼ 0.223).
Similar results were obtained using the absolute FEV1 change from
baseline; attenuation of 20.3% with CHF6001 400 mg (p ¼ 0.014) and
29.9%withCHF60011200mg (p<0.001) comparedwithplacebowere
observed,with nodifference betweenCHF6001doses. Themaximum
FEV1% fall was attenuated by CHF6001 400 mg and 1200 mg (15.6%;
p ¼ 0.028 and 22.9%; p ¼ 0.001 respectively). There were similar re-
sults for the maximum absolute FEV1 fall (L) (Table 2).
CHF6001 400 mg and 1200 mg had no signiﬁcant effect on the
EAR AUC0e2h (% change) or maximum fall compared to placebo
(Table 2).
3.2. Pulmonary function before allergen challenge
FEV1 measured pre-dose on days 4 and 9 were similar to base-
line values for CHF6001 and placebo (see on-line Table 1).3.3. Methacholine challenge
The methacholine PC20 FEV1 geometric means (95% CI) 24 h
post-allergen challenge were 0.652 (0.499; 0.851), 0.826 (0.627;
1.088) and 0.505 (0.378; 0.674) mg/mL after treatment with
CHF60011200 mg, CHF6001 400 mg and placebo, respectively. There
was a statistically signiﬁcant difference in MCh PC20 FEV1 of 0.7
doubling doses between CHF6001 400 mg and placebo (p ¼ 0.028).
The doubling dose difference between CHF6001 1200 mg and pla-
cebo was 0.4 (p ¼ 0.331).
3.4. Induced sputum
The numbers of viable sputum samples obtained after treatment
with CHF6001 1200 mg, CHF6001 400 mg and placebo were 14, 14
and 17 respectively. Eosinophil counts are shown in Table 3.
Compared with placebo, CHF 6001 caused greater reductions in
eosinophil absolute counts and percentages, although these
changes did not attain statistical signiﬁcance. There were no dif-
ferences for other cells types, or ECP or NE concentrations, as
shown in on-line Table 2.
3.5. Pharmacokinetics
Plasma concentrations of CHF6001 and the metabolite CHF5956
on day 9 are shown in Fig. 2. The systemic exposure to CHF6001
was proportional to the dose administered, with AUC0t geometric
means of 4,960 h pg/mL and 14,746 h pg/mL for CHF6001 400 mg
and 1200 mg, respectively, indicating an approximately three times
higher systemic exposure with a 3-fold increase in the dose. The
Cmax geometric means followed a similar pattern; CHF6001346 pg/
mL and 1,025 pg/mL for 400 mg and 1200 mg, respectively.
CHF5696 pharmacokinetics also showed a relationship to the
dose administered, with AUC0t geometric means of 166 h pg/mL
and 813 h pg/mL for CHF6001400 mg and 1200 mg, respectively. The
Cmax geometric means followed a similar pattern; 34.6 pg/mL and
95.8 pg/mL for CHF6001 400 mg and 1200 mg, respectively.
3.6. Adverse events
Adverse events were reported by similar numbers of patients
within each treatment period; 38.2% and 30.3% for CHF6001400 mg
and 1200 mg, respectively, and 37.1% for placebo. Adverse events
weremostly mild in nature, the most common being headache (see
on-line Table 3). Gastrointestinal adverse events were uncommon,
with one episode of dyspepsia during CHF6001 400 mg treatment
and one during placebo treatment.
4. Discussion
This clinical trial was designed to evaluate the efﬁcacy of the
Fig. 1. Time course of FEV1 changes after allergen challenge conducted after 9 days dosing. Adjusted mean % change in FEV1 (from post diluent value) is shown on y-axis. Error bars
represent SEM.
Table 2
Late and early asthmatic response (FEV1 weighted mean AUC and maximum fall) after 9 days treatment.
Treatment effect Difference versus placebo
PEa (95%CI) PEa (95%CI)b p-valueb % of reduction
LAR
AUC 4e10 h (%) 400mcg 16.70 (18.73; 14.68) 4.09 (0.73; 7.45) 0.015 19.7%
1200mcg 14.94 (16.96; 12.92) 5.86 (2.49; 9.23) <0.001 28.2%
Placebo 20.80 (22.98; 18.62) e e e e
AUC 4e10 h (L) 400mcg 0.552 (0.621; 0.483) 0.141 (0.026; 0.256) 0.014 20.3%
1200mcg 0.486 (0.555; 0.417) 0.207 (0.092; 0.322) <0.001 29.9%
Placebo 0.693 (0.767; 0.618) e e e e
Max Fall (%) 400mcg 26.07 (28.70; 23.44) 4.84 (0.47; 9.20) 0.028 15.6%
1200mcg 23.84 (26.47; 21.21) 7.06 (2.69; 11.44) 0.001 22.9%
Placebo 30.91 (33.74; 28.07) e e e e
Max fall (L) 400mcg 0.865 (0.956; 0.775) 0.168 (0.017; 0.318) 0.027 16.3%
1200mcg 0.782 (0.873; 0.691) 0.251 (0.100; 0.402) <0.001 24.3%
Placebo 1.033 (1.131; 0.935) e e e e
EAR
AUC0-2 h (%) 400mcg 15.417 (17.760; 13.074) 0.698 (3.09; 4.49) 0.881 4.3%
1200mcg 14.901 (17.244; 12.558) 1.214 (2.58; 5.01) 0.690 7.5%
Placebo 16.115 (18.511; 13.720) e e e e
AUC0-2 h (L) 400mcg 0.511 (0.583; 0.440) 0.035 (0.081; 0.151) 0.712 6.4%
1200mcg 0.487 (0.558; 0.415) 0.060 (0.056; 0.176) 0.401 11.0%
Placebo 0.547 (0.620; 0.473) e e e e
Max Fall (%) 400mcg 27.710 (30.646; 24.774) 2.390 (2.36; 7.14) 0.419 7.9%
1200mcg 26.755 (29.691; 23.818) 3.346 (1.41; 8.10) 0.201 11.1%
Placebo 30.100 (33.103; 27.098) e e e e
Max fall (L) 400mcg 0.916 (1.008; 0.825) 0.092 (0.056; 0.240) 0.277 9.1%
1200mcg 0.889 (0.981; 0.798) 0.119 (0.029; 0.267) 0.131 11.8%
Placebo 1.008 (1.102; 0.915) e e e e
a PE ¼ Point Estimate.
b Dunnett’s adjustment.
Table 3
Sputum percent differential cell count.
Placebo N ¼ 17 CHF 400mcg N ¼ 14 CHF 1200mcg N ¼ 14
Eosinophil % 7.1 (4.6;10.8) 5.4 (3.4;8.8) 4.4 (2.7;7.1)
Neutrophil % 65.5 (58.4;73.5) 71.8 (62.9;81.8) 69.2 (60.6;78.9)
Macrophage % 12.2 (8.8;16.8) 6.9 (4.8;10.1) 10.5 (7.2;15.3)
Lymphocyte % 0.0 (0.0;0.0) 0.0 (0.0;0.0) 0.0 (0.0;0.0)
Data are adjusted geometric means and 95% conﬁdence interval.
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allergen in patients with mild atopic asthma. CHF6001 signiﬁcantly
reduced the LAR, and was also well tolerated. Since orally admin-
istered PDE4 inhibitors cause side effects due to systemic exposure
[3e5], CHF6001 has the potential for a better therapeutic index due
to targeted lung delivery thereby markedly reducing systemic
exposure.
There has been interest recently in the re-evaluation of the use
of PDE4 inhibitors for the treatment of asthma [5,6,13]. A review of
placebo controlled clinical trials in asthma using roﬂumilast re-
ported a beneﬁt in terms of lung function, including when
administered in addition to inhaled corticosteroids [6]. However,
further evidence for the symptomatic beneﬁts of PDE4 inhibitors in
asthma are needed. This study shows inhibition of allergic
inﬂammation by CHF6001. Inhibition of the LAR has become a
standard method for investigating the potential of novel drugs tosuppress the allergic component of inﬂammation in asthma, as a
lack of effect on the LAR indicates that such drugs will not be useful
clinical treatments for allergic asthma [8,14]. This study conﬁrms
the potential for CHF6001 as a treatment for asthma, but further
studies to investigate long term effects on lung function and
symptoms are needed.
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inhibitors roﬂumilast [11,15] and MEM1414 [16], and the inhaled
PDE4 inhibitor GSK256066 [17] inhibited the LAR, with effect sizes
ranging from approximately 20e43% depending on the endpoint
measured (AUC or maximum fall). In the current study, the level of
inhibition of the LAR AUC of approximately 20e30% (varying ac-
cording to the CHF6001 dose) was similar to these previous results.
Comparisons between different allergen challenge studies are to be
taken with caution due to important methodological differences,
including the period of measurement of the LAR.
The lack of effect of CHF6001 on the EAR may indicate that this
PDE4 inhibitor does not inﬂuence mast cell degranulation, as is the
case for inhaled corticosteroids [18,19]. Previous allergen challenge
studies using PDE4 inhibitors have shown variable EAR results,
with both inhibition [11,15,17] and no inhibition [16,20] observed.
This study was speciﬁcally powered for the primary endpoint of
the LAR FEV1 AUC, and we observed approximately 20e30%
reduction in this parameter. The 1200 mg dose caused a numerically
greater effect than 400 mg on the LAR (approximately 10% differ-
ence), but these differences were not statistically signiﬁcant. It
should be noted that the study was powered on the basis of a 30%
difference between active treatment and placebo, and so the lack of
statistical signiﬁcance between the active treatments with a 10%
treatment difference is likely to be related to insufﬁcient statistical
power.
The pharmacokinetic analysis showed a linear relationship be-
tween systemic exposure and the dose of CHF6001, as AUC0t
(geometric mean) was approximately 3 times higher for the
1200 mg dose compared with 400 mg. The increased exposure with
1200 mg appears to be associated with greater efﬁcacy on the LAR
(albeit not statistically signiﬁcant) for the reasons already
explained, but no increase in side effects. Indeed, the incidence and
nature of side effects with inhaled CHF6001 were similar to pla-
cebo; this is encouraging for the further clinical development of
this drug, as side effects of oral PDE4 inhibitors such as gastro-
intestinal disturbance, headache and weight loss are a concern in
clinical practice. Although this was a short term study, gastro-
intestinal disturbance caused by PDE4 inhibitors tends to occur
early after starting therapy [3e5,21], and so it is promising that
there was an absence of this signal in the current study.
The LAR involves an inﬂux of inﬂammatory cells into the air-
ways, including eosinophils [22]. CHF6001 caused a reduction in
sputum eosinophil counts after allergen challenge, although not
statistically signiﬁcant. A subset of 20 patients who were able to
produce adequate sputum samples at screening was speciﬁcally
recruited, in order to enrich the study population with individuals
who were more likely to produce good quality samples after
allergen challenge. During the treatment periods, the number ofFig. 2. Pharmacokinetic proﬁles of CHF6001 and CHF5sputum samples ranged from 14 to 17. The study was not powered
for sputum eosinophils, and we saw a numerical suppression of
these cells by CHF6001 that was not statistically signiﬁcant. A
larger sample size is probably needed to robustly evaluate this
endpoint.
Despite the positive effect of CHF6001 on the primary endpoint
(LAR), no consistent effect on secondary endpoints, including
induced sputum and methacholine challenge conducted after
allergen challenge was observed. However, the study was not
powered for these secondary endpoints, and many other previous
allergen challenge studies of novel therapies have also shown
positive efﬁcacy on the primary LAR endpoints but failed to show
efﬁcacy on secondary endpoints such as methacholine challenge
[8,10,17,18,23].
The FEV1 measurements on days 4 and 9 (before allergen chal-
lenge) showed no change compared to baseline. This might be due
to the very short term treatment with CHF6001 and the very mild
airway obstruction of enrolled patients.
Inhaled PDE4 inhibitors, such as CHF6001, are likely to be used
as add on to inhaled corticosteroid plus long acting beta agonist.
Bateman et al. recently reported that roﬂumilast added to inhaled
corticosteroid plus long acting beta agonist plus leukotriene
antagonist treatment resulted in an FEV1 improvement of approx-
imately 100 ml [24]. This demonstrates the potential for PDE4 in-
hibitors as add on treatment to other standard asthma therapies.
The current study was performed in asthma patients who were
not taking ICS, in order to avoid any confounding effect of ICS
treatment on the response to inhaled allergen challenge. This is the
population used for most allergen challenge studies of novel drugs
for asthma [8e11], and the demonstration of a positive effect using
this study design usually encourages further studies of longer
duration in moderate to severe asthma patients. The effects of
CHF6001 in mild asthma patients not taking ICS observed here also
suggests that longer clinical trials could bewarranted in this patient
group. However, the ﬁrmly established place of ICS as a ﬁrst line
maintenance treatment for asthma makes it difﬁcult for any novel
anti-inﬂammatory drug to be a recognised treatment before ICS.
The patients in this study all demonstrated a positive LAR.
Clinical trials in asthma patients often require the demonstration of
either bronchodilator reversibility or methacholine reactivity at
screening to conﬁrm the diagnosis of asthma.We used the presence
of an LAR as conﬁrmation, and so did not perform other conﬁr-
matory tests.
In conclusion, the inhaled PDE4 inhibitor CHF6001 signiﬁcantly
reduced the LAR in patients with atopic asthma. Further studies of
the long-term efﬁcacy and safety of CHF6001 are now needed, as
inhaled delivery of this drug has the potential to provide clinical
beneﬁts with an acceptable safety proﬁle.956 after 9 days dosing. Mean values are shown.
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